Newsroom

₹110 Crore strategic investment from Piramal Alternatives

Company News12 November 2024Biodeal Communications

A landmark institutional investment to scale injectable capacity, strengthen our nasal spray leadership and expand export infrastructure.

More details coming soon.

Media & press

Working on a story?

For press enquiries, interviews, company facts or media assets, reach our communications team — we typically respond within 48 business hours.

Media enquiry Contact & officesinfo@biodealpharma.com · +91 120-6025048